Search

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

EHA-Balkan Hematology Day 2021

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 2nd edition of the EHA-Balkan Hematology Day.

Read more

IVDR resources

IVD Taskforce Videos:Konstanze Döhner

\
 

Monika Brüggemann

IVDR Sessions:

HemaSphere articles:
Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force
The New EU Regulation on In Vitro Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories
EU-Wide Access to…

Read more

Dutch scientists propose algorithm to keep drugs affordable and accessible

May 8, 2018, The Hague - An important contribution to the debate about the affordability and accessibility of innovative medicines appeared in Nature Reviews, proposing the adoption of a novel model of price setting with examples of implementation.

Read more

Registration & accommodation

Register here

Individual RegistrationRegistration fee includes:

Access to the scientific and educational sessions of the meeting. Digital meeting materials including the program and abstract book. Networking opportunities during breaks, receptions and dinners.

Read more

EHA-ASH Translational Research Training in Hematology

TRTH 2025 call is now closed. What is Translational Research Training in Hematology?Translational Research Training in Hematology (TRTH) provides early-career researchers with a unique, year-long training and mentoring experience.

Read more

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

Leading Medical Organizations Join Forces Globally to Launch First-Ever World Thrombosis Day

“We must reduce the burden from thrombosis if we are to achieve the World Health Assembly’s global target of reducing mortality from premature non-communicable disease by 25 percent by 2025,” said Gary Raskob, Ph. D.

Read more